Congress extends ALS research funding, tightens safety reporting requirements
S. 4472 — Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026 · Filed by Lisa Murkowski (R-AK) · 15 cosponsors · Introduced Apr 30, 2026 · Passed chamber
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill extends the Accelerating Access to Critical Therapies for ALS Act through 2031, expanding the federal program that funds research grants for ALS treatments and therapies. It improves grant application requirements to ensure better data collection and safety reporting, broadens the program to include other rare neurodegenerative diseases, and adds new reporting requirements to track program effectiveness.
Why we flagged it
The bill's core function is to extend and improve a federal research-funding program for ALS and rare neurodegenerative diseases. It is a straightforward reauthorization with technical improvements to grant administration and reporting.
What the text implies
- Expansion to 'other rare neurodegenerative diseases' beyond ALS may broaden research funding scope without explicit appropriations language, potentially affecting budget allocation across multiple disease areas.
- New safety-data reporting requirements from ongoing clinical trials may increase administrative burden on grant recipients and sponsors, potentially affecting participation rates or grant application timelines.
The full analysis lists 3 implications of this text.
Who stands to gain
Academic medical centers and research institutions receiving ALS/neurodegenerative disease grants; Pharmaceutical companies sponsoring investigational drug applications (through expanded access data